On 17 April 2025, Roche released a community letter announcing that GENERATION HD2 will continue following planned interim analysis by the independent Data Monitoring Committee. Enrollment has completed for this randomised, double-blind study of tominersen, but participants on the 60 mg dose will move to the higher dose (100 mg every 16 weeks), given the greater potential for clinical benefit combined with an absence of safety concerns. Participants, researchers, and Roche staff remain blinded to treatment assignment (placebo vs active drug) and the study is expected to complete in 2026.
 
For details of all ongoing and completed EHDN-endorsed studies, click here.